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Abstract 
 
Aims/hypothesis  Circulating fibroblast growth factor 21 (FGF21) levels are often elevated in 
obesity, dyslipidaemia, insulin resistance and type 2 diabetes.  This study investigated the 
relationship of plasma FGF21 levels with cardiovascular events in patients with type 2 
diabetes. 
Methods  Plasma FGF21 levels were measured at baseline in 9,697 study participants with 
type 2 diabetes from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) 
study by enzyme-linked immunosorbent assay.  We assessed the association of FGF21 levels 
with incidence of different cardiovascular outcomes over 5-years.  The primary outcome was 
total cardiovascular disease (CVD) events, and the secondary outcomes were the four 
individual components: coronary heart disease (CHD) events, total stroke, CVD mortality, 
coronary and carotid revascularization.  Tertiary outcome was hospitalisation for angina 
pectoris. 
Results  Higher baseline FGF21 levels were associated with higher risks of all cardiovascular 
outcome events after adjusting for the study treatment allocation (all p<0.01).  The 
associations remained significant for total CVD events, and coronary and carotid 
revascularisation after further adjusting for confounding factors with HR (95% CI) being  
1.28 (1.10, 1.50) and 1.26 (1.01, 1.56) respectively, for the highest tertile compared to the 
lowest tertile (overall effect p=0.002 and 0.007 respectively).  The addition of FGF21 levels 
to a model including established CVD risk factors predicting total CVD led to a non-
significant increase in the C-statistic, but resulted in significant integrated discrimination 
improvement and net reclassification improvement.  
Conclusions/interpretation  Higher baseline plasma FGF21 levels were associated with 
higher risk of cardiovascular events in patients with type 2 diabetes.   
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CVD  Cardiovascular disease 
FGF21  Fibroblast growth factor 21 
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NRI  net reclassification improvement 
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Introduction 
 
Fibroblast growth factor 21 (FGF21) is a novel metabolic regulator [1-4].  In animal 
studies, FGF21 has anti-inflammatory, anti-diabetic and hypolipidaemic effects [1, 5, 6].  
However, in human studies, circulating FGF21 levels are often elevated in obesity, 
dyslipidaemia, insulin resistance, type 2 diabetes, non-alcoholic fatty liver disease and 
coronary artery disease [4, 7-10].  The elevation in FGF21 levels may be a compensatory 
response to underlying metabolic stress or due to impaired FGF21 signalling leading to 
FGF21 resistance [4].  In recent years, several pharmaceutical companies have carried out 
preclinical studies to investigate the benefits of FGF21-based therapies in diabetes and 
obesity-associated disorders [11-13].  In a recent proof-of-concept trial, daily subcutaneous 
injection of a variant of FGF21 resulted in favourable changes in lipid levels, lipoprotein 
profile, body weight, fasting insulin and adiponectin levels in obese patients with type 2 
diabetes [14].  Recent animal studies have also demonstrated a cardioprotective effect of 
FGF21 [15, 16]. 
 
The aim of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) 
study was to investigate the effect of long-term lipid-lowering treatment with fenofibrate on 
adverse macrovascular outcomes in patients with type 2 diabetes [17].  In the FIELD study, 
although fenofibrate therapy did not significantly reduce the primary outcome of major 
coronary events over 5 years, it did reduce the main pre-specified secondary endpoint of total 
cardiovascular disease (CVD) events in patients with type 2 diabetes [18].  There are very 
limited data in the literature on the relationship of circulating FGF21 levels with CVD events 
in a large-scale, well-designed cohort.  The size of the FIELD trial (n=9,795) and number of 
cardiovascular events provide a unique opportunity to examine the relationship of FGF21 
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levels to cardiovascular risk.  Therefore, in this 5-year study, we investigated whether 
circulating FGF21 levels were associated with any cardiovascular outcome events, and 
whether FGF21 levels can provide incremental information on risk stratification compared to 
a model using traditional cardiovascular risk factors alone. 
 
Methods 
Study design   
The study design, baseline subject characteristics and major findings of the FIELD 
study have been described previously [17-21].  Briefly, the FIELD study was a double-blind 
placebo-controlled randomised trial, involving a total of 9,795 patients with type 2 diabetes 
recruited into the study between February 1998 and November 2000.  All patients were aged 
50-75 years and randomly allocated to once-daily co-micronized fenofibrate 200 mg or 
matching placebo for 5 years (International Standard Randomised Controlled Trial number 
ISRCTN64783481).  The study protocol was approved by national and local ethics 
committees.  The study was undertaken in accordance with the Declaration of Helsinki and 
Good Clinical Practice Guidelines.  All study patients gave written consent.   
 
Plasma FGF21 measurement   
In the present study, 9,697 (99.0%) out of 9,795 patients from the FIELD study had 
plasma samples at baseline available for FGF21 measurement.  In a separate analysis, plasma 
FGF21 levels were also measured in a random sub-sample of 1,919 patients (62.4% males 
and 49.8% in the fenofibrate treatment group) at one year to assess the effect of fenofibrate 
treatment.  FGF21 levels were measured using enzyme-linked immunosorbent assay kits 
(Antibody and Immunoassay Services, University of Hong Kong, Hong Kong) as described 
previously in our pilot study [22].  Briefly 60 µl of plasma sample was diluted 1:1 (v:v) with 
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assay diluent and analysed together with quality controls as per manufacturer’s instruction.  
The intra-assay and inter-assay coefficients of variation were <6%.  All samples were 
analysed masked for patient identity and study treatment allocation. 
 
Other variables of interest   
The measurement methods of clinical characteristics, and details on the primary 
endpoint and other outcomes of the FIELD trial have been described previously [17-24].  In 
this analysis, as specified for all FIELD biomarker analyses, the primary outcome was total 
CVD events (coronary heart disease (CHD) events, total stroke and other cardiovascular 
death events plus coronary and carotid revascularization).  The secondary outcomes in this 
analysis were the individual components of total CVD events, i.e. CHD event, total stroke, 
CVD mortality, and coronary and carotid revascularization.  In this study, we also analysed 
the tertiary outcome of hospital admission for angina pectoris which included unstable 
angina, other forms of angina pectoris and unspecified angina pectoris with matched codes of 
I20.0, I20.8 and I20.9 by ICD-10.  In an exploratory analysis, the outcomes of CHD events, 
total stroke and CVD mortality were combined as the hard endpoint.  Previous CVD 
comprised angina, myocardial infarction, coronary artery bypass grafting, percutaneous 
transluminal coronary angioplasty, stroke, peripheral vascular disease and revascularisation.  
Estimated GFR was calculated by the four-variable Modification of Diet in Renal Disease 
formula [25]. 
 
Statistical analysis 
Statistical analysis was performed using SPSS 22 (IBM, Armonk, NY) or STATA 13.0 
(StataCorp, College Station, TX).  The relative changes of FGF21 levels from baseline to one 
year were calculated after loge-transformation, i.e., the average difference in loge-transformed 
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FGF21 levels was exponentiated to obtain a ratio which was rescaled by subtracting 1 and 
multiplying by 100 to derive the relative change.  Treatment effect was derived from the ratio 
of treatment-specific ratios for the fenofibrate group relative to the placebo group.  Cox 
regression was used to compute HR and its 95% CIs to assess the association of FGF21 levels 
at baseline with different outcome events.  As FGF21 level was highly skewed, data were 
analysed after loge transformation to achieve a more linear relationship with outcomes.  Tests 
for deviation from linearity indicated a significant deviation from linearity for the outcome of 
coronary and carotid revascularization, but not for other outcomes [26].  Therefore, tertiles of 
baseline FGF21 levels were used as the main analysis.  The p value for the overall effect of 
FGF21 tertile was calculated by testing the hypothesis that the HR estimates of both tertiles 2 
and 3 were equal to one.  The incremental value of the addition of loge-transformed FGF21 
levels in the risk prediction model was assessed by the change in Harrell's C-statistic using a 
method adapted for survival models, integrated discrimination improvement (IDI) and the 
category-free net reclassification improvement (NRI) as described previously [27-29].  The 
goodness of fit of the models was assessed using the Gronnesby and Borgan test [30].  See 
the online Electronic Supplementary Material (ESM) Methods for further details. 
 
In this analysis, the principal pre-specified analysis was the association of baseline 
FGF21 levels with different outcomes in Cox regression analysis.  A two-sided p value <0.05 
was considered significant for the primary outcome; p<0.01 for the secondary outcomes and 
p<0.001 for tertiary outcome.  For the post-hoc analysis of the association of FGF21 levels 
with hard endpoint, and the subgroup analysis of total CVD events, a p value <0.01 was 
considered significant.  A two-sided p value <0.05 was considered significant for all other 
analyses.   
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Results 
Baseline characteristics 
There were no significant differences in age, sex, BMI, waist-to-hip ratio, known 
diabetes duration, and percentage of prior CVD between the 9,697 patients with baseline 
FGF21 levels measured and the other 98 subjects without measurement (all p>0.05) (ESM 
Table 1).  The median value (IQR) of baseline plasma FGF21 was 316 (205-482) pg/ml.  
Table 1 shows the clinical characteristics of all the patients according to tertiles of FGF21 
levels at baseline.   
 
Effect of fenofibrate therapy on FGF21 levels 
Plasma FGF21 levels increased over one year by about 101.5% in the fenofibrate 
group, but only 11.2% in the placebo group compared to baseline levels.  Fenofibrate 
increased plasma FGF21 levels by 81% (95% CI 72%, 90%) relative to placebo over one year 
(p<0.001).  Although women had higher FGF21 levels than men at baseline and after one-
year (all p<0.01), the effect of fenofibrate therapy on relative change in plasma FGF21 was 
similar in both men and women (ESM Table 2).   
 
Association of FGF21 levels with baseline characteristics 
As shown in ESM Table 3, higher age, BMI, waist-to-hip ratio, fasting glucose, 
HOMA-IR, triacylglycerol, plasma creatinine and homocysteine as well as female sex, 
smoking and prior history of CVD were independently associated with higher FGF21 levels, 
while longer known diabetes duration, and higher LDL cholesterol, HbA1c and fibrinogen 
were associated with lower FGF21 levels.  In a separate analysis, the effect of concomitant 
use of baseline glucose lowering and cardiovascular medications on FGF21 levels was 
analysed.  For glycaemic control, compared to diet therapy, the use of oral agents (mainly 
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metformin and/or sulfonylurea) was associated with higher FGF21 levels (p=0.009), whereas 
the use of insulin was associated with lower FGF21 levels (p<0.001) (ESM Table 4).  For 
cardiovascular medication, the use of aspirin was associated with lower FGF21 levels 
(p=0.02), whereas the use of diuretic was associated with higher FGF21 levels (p<0.001) 
(ESM Table 5). 
 
Association of baseline FGF21 levels with cardiovascular events 
Among 9,697 patients with valid data on FGF21 levels, 1,281 patients developed total 
CVD events, 537 developed CHD events, 330 developed stroke, 266 developed CVD 
mortality, 691 developed coronary and carotid revascularisation, and 455 needed 
hospitalisation for angina pectoris during a median follow-up period of 5 years.  Table 2 
shows the association of tertiles of plasma FGF21 levels at baseline with different outcome 
events over 5 years.  When only adjusting for treatment allocation, higher tertiles of plasma 
FGF21 levels were associated with higher risks of all outcome events (all overall effect 
p<0.01).  However, the association remained significant only for total CVD events (p=0.002), 
and coronary and carotid revascularization (p=0.007) after adjusting for confounding factors 
(Table 2 and Fig. 1a).  Associations were demonstrated for total stroke and hospitalisation for 
angina pectoris however they did not meet the pre-specified criteria for a ‘significant’ p value 
for secondary and tertiary outcomes.  Figure 1b shows the cumulative first event rates over 5 
years by tertile of baseline FGF21 levels for all the outcomes.  A significant interaction with 
treatment allocation was found for total CVD events, in which the association was significant 
in the placebo group, but not the fenofibrate group (overall effect p<0.001 and p=0.19 
respectively, p for interaction =0.04) (Table 2).  In a separate analysis, similar results were 
obtained for the association of FGF21 tertiles with different outcome events after further 
adjusting for glucose lowering medication, aspirin and diuretic (FGF21 tertile overall effect: 
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total CVD events, p=0.002; CHD event, p=0.22; total stroke, p=0.04; CVD mortality, p=0.81; 
coronary and carotid revascularization, p=0.006; hospitalisation for angina pectoris, 
p=0.006).  In an exploratory analysis when the outcomes of CHD event, total stroke and 
CVD mortality were combined as a hard endpoint, the association of FGF21 levels did not 
reach the pre-specified p value criteria for significance for post-hoc analysis (ESM Table 6).  
Similar results were obtained when loge-transformed FGF21 levels, instead of FGF21 tertiles, 
were used in the analysis although the interaction with treatment allocation was not 
significant for total CVD events (ESM Table 7).   
 
Discrimination and reclassification 
The addition of FGF21 level to a model adjusted for traditional cardiovascular risk 
factors resulted in a modest, but significant, increase in the C-statistic for hospitalisation for 
angina pectoris from 0.692 to 0.698 (p=0.03), but not other outcomes (ESM Table 8).  The 
IDI analysis showed a modest, but significant, improvement for total CVD events and total 
stroke (Table 3).   When assessing the reclassification using the category-free NRI, the 
addition of FGF21 levels to a model with traditional cardiovascular risk factors resulted in a 
significant increase in the NRI for total CVD events, total stroke, and hospitalisation for 
angina pectoris (Table 3).  In all these analyses, similar results were obtained when tertiles of 
FGF21 levels were used in the models (data not shown). 
 
Association of baseline FGF21 levels with total CVD events in different subgroups 
As the outcome of total CVD events had the largest number of cases, a post-hoc 
subgroup analysis was then performed according to some clinical characteristics, including 
glycaemic and lipid profiles among the placebo group.  As shown in ESM Table 9, the 
association of tertiles of plasma FGF21 level with total CVD events did not show any 
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significant interaction with age, sex, previous history of CVD, BMI, smoking, known 
diabetes duration, HbA1c, HDL cholesterol, LDL cholesterol, triacylglycerol and estimated 
GFR (all p for interaction >0.10). An interaction was demonstrated with total cholesterol, in 
which the association tended to be stronger in patients with higher total cholesterol (p for 
interaction =0.009).  
 
Discussion 
FGF21 is a metabolic hormone which is produced predominantly in the liver [4].  It is 
also produced and secreted by cardiac cells [15].  In a recent study, mice lacking FGF21 
showed enhanced cardiac hypertrophy, while treatment with FGF21 protected against the 
hypertrophic response [15].  In another recent study, FGF21 administration was shown to 
mitigate myocardial infarction in response to experimental myocardial ischaemia in mice 
[16].  The present study is the first report of the association of plasma FGF21 level with 
different cardiovascular outcome events in a large-scale, well-designed clinical trial 
conducted in patients with type 2 diabetes.    
 
In this 5-year follow-up study, plasma FGF21 levels at baseline were associated with 
total CVD events, and coronary and carotid revascularisation.  Similar trends were also seen 
for other outcomes, although these associations lost their significance after adjusting for 
multiple other baseline characteristics.  The findings were generally similar in both treatment 
arms of the study.  This is consistent with previous reports showing elevated FGF21 levels in 
different human metabolic disease states such as obesity, the metabolic syndrome and type 2 
diabetes, even though FGF21 shows anti-inflammatory, anti-diabetic and hypolipidaemic 
properties in animal studies [4].  In a previous cross-sectional study, serum FGF21 level was 
higher in 135 patients with CHD, compared with 35 control subjects [9].  In two other recent 
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cross-sectional studies, higher serum FGF21 was associated with higher risk of coronary 
artery disease [31] and carotid atherosclerosis [32], both independent of other traditional 
cardiovascular risk factors.  In a recent small study of 87 patients with type 2 diabetes, higher 
serum FGF21 levels were associated with a higher risk of the combined end point of 
cardiovascular morbidity and mortality during a 24-month follow-up period [33].  In another 
recent study of 60 subjects with CAD and 129 BMI-matched subjects without CAD, serum 
FGF21 levels was not associated with current coronary artery status, but was associated with  
hypertriglyceridaemia, hyperinsulinaemia pericardial fat accumulation and the metabolic 
syndrome, independently of obesity [34].  The elevation in FGF21 has been suggested to be 
due to FGF21 resistance (as a result of impaired FGF21 signalling) or it may be a 
compensatory response [4].  Our study is the largest prospective study to assess the 
association of FGF21 levels at baseline with different cardiovascular events.   
 
For total CVD events, the overall association of FGF21 levels at baseline was also 
found separately in the placebo group, but not the fenofibrate group, although such difference 
by treatment only reached statistical significance when assessing the FGF21 level as a tertile 
variable, but not as a loge-transformed variable.  We previously reported that fenofibrate 
treatment increased FGF21 levels by 85% relative to placebo over 5 years in a pilot study of 
216 patients from the FIELD trial [22].  In the present study, fenofibrate treatment was also 
found to increase FGF21 levels to a similar extent (i.e. 81%) relative to placebo over one 
year.  In our previous study, the change in FGF21 levels by fenofibrate treatment over 5 years 
tended to be greater in patients with lower FGF21 levels at baseline [22].  This differential 
increase in FGF21 levels according to baseline FGF21 levels in the fenofibrate group may 
thus confound the association of baseline FGF21 levels with outcome events.  Nevertheless, 
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further studies are needed to elucidate the non-significant association in the fenofibrate 
group. 
 
In this study, we assessed the incremental value of the addition of FGF21 levels in a 
risk prediction model with established risk factors using C-statistics, IDI and category-free 
NRI.  The results of these analyses suggested that plasma FGF21 levels could provide 
incremental information for total CVD events and FGF21 may be a potential biomarker for 
risk assessment of some CVD events.  However, interpretation should be cautious as the 
improvement in C-statistics and IDI was only modest and there was no outcome event that 
showed significant positive results in all three different analyses.  Nevertheless, for the events 
other than the total CVD event outcome, numbers of events and hence power for analyses 
was substantially lower, and the small incremental value seen here is typical of models that 
already consist of strong and well-established risk factors [35, 36].   
 
In a subgroup analysis among the placebo group of the FIELD study, the association 
of FGF21 with total CVD events did not differ significantly by most clinical characteristics, 
except total cholesterol.  This suggests that FGF21 could be a potential cardiovascular 
biomarker for patients with type 2 diabetes regardless of their glycaemic control and the 
presence of other cardiovascular risk factors such as previous history of CVD, obesity and 
smoking.  It is interesting that the association of FGF21 with total CVD events tended to be 
stronger in patients with higher total cholesterol.  In fact, recent studies have suggested that 
FGF21 may play a role in cholesterol metabolism [37-39]. 
 
FGF21 has demonstrated favourable metabolic and cardioprotective properties in 
animal studies [1, 5, 6, 15, 16] as well as in a recent proof-of-concept human clinical trial 
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[14].  This may seem contradictory as higher baseline FGF21 levels were associated with 
higher CVD risk.  It does, however, indicate that an elevated circulating level of FGF21 may 
be implicated as a potential biomarker for the early detection of different cardiometabolic 
disorders [4].  The elevation of FGF21 could be a compensatory protective response to 
underlying metabolic stress or due to FGF21 resistance as a result of impaired FGF21 
signalling, which implies the need for supraphysiological doses of FGF21 to achieve 
therapeutic efficacy [4].  In the proof-of-concept human clinical trial, the circulating levels of 
the FGF21 variant, LY2405319, were 30-300 fold higher than the physiological levels of 
plasma FGF21 [14].  It may also seem contradictory as some CVD risk factors, such as 
longer known diabetes duration, higher HbA1c levels, LDL cholesterol levels, fibrinogen 
levels, and use of insulin medication were associated with lower, not higher, FGF21 levels.  
The reason for this is uncertain.  However, previous studies have also reported the association 
of higher FGF21 levels with lower LDL cholesterol levels in pregnancy [40] and in chronic 
kidney disease patients [41, 42].  In another study, patients with type 2 diabetes and higher 
FGF21 levels had shorter diabetes duration than patients with lower FGF21 levels although 
the difference did not reach statistical significance [33].   These findings indicate that further 
clinical studies are needed to elucidate the systemic role and regulation of FGF21 levels in 
CVD in patients with type 2 diabetes. 
 
Our study has the advantages of making use of the FIELD study, which is well 
designed and has good quality control, a large sample size, standardised assessments of 
different clinical characteristics and outcome events, and availability of data on many 
different outcome events.  However, there are also several limitations in our study.  In this 
analysis, different outcomes were assessed at the same time and thus there may be a chance 
of false positive results due to multiple testing.  However, these outcome events were all pre-
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specified in the FIELD study, adjudicated by a committee masked to study treatment 
allocation.  The analysis of different outcome events also allowed us to gain further 
understanding on the role of FGF21 in cardiovascular outcomes in people with type 2 
diabetes.  As all the patients in the FIELD study had type 2 diabetes at baseline, the findings 
from this study may not be generalizable into healthy people or other people at high risk of 
CVD, but without diabetes.  This is particularly important because patients with type 2 
diabetes have been reported to have elevated FGF21 levels [4, 10, 43].  Further studies in 
different clinical settings, or with different subject characteristics, are needed to confirm our 
findings from the FIELD study. 
 
In summary, higher plasma FGF21 levels at baseline were associated with higher risk 
of cardiovascular outcomes in the FIELD study and could be a compensatory protective 
response to underlying metabolic stress or impaired FGF21 signaling leading to FGF21 
resistance.  Studies of treatments which modify FGF21 levels and may influence 
cardiovascular risk would be justified. 
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Figure legends 
 
 
Fig. 1 Association of plasma FGF21 levels at baseline with outcome events over 5 years.  (a) 
HR values by tertile of FGF21 levels are shown for each event type; (b) cumulative first 
event rates over 5 years are shown by tertile for all events.  All HR and P values were 
adjusted for age, sex, known diabetes duration, prior history of CVD, smoking (never, former 
and current), BMI, HbA1c, HOMA-IR, systolic BP, HDL cholesterol, LDL cholesterol, 
triacylglycerol, fibrinogen, plasma creatinine and homocysteine at baseline, and treatment 
allocation.  Error bar indicates 95% CI.  White bars, FGF21 tertile 1; grey bars, FGF21 tertile 
2; black bars, FGF21 tertile 3.  *Significant interaction with the treatment allocation 
(p<0.05).   
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 Table 1  Characteristics of patients at baseline according to baseline plasma FGF21 levels 
Characteristics Tertile 1 
(<239.3 pg/ml) 
Tertile 2 
(239.3 - <412.8 
pg/ml) 
Tertile 3 
(≥412.8 pg/ml) 
n 3,232 3,233 3,232 
FGF21 (pg/ml) 170 (127-205) 316 (276-360) 585 (482-786) 
Age (years) 61.8±6.8 62.3±6.9 62.6±6.9 
Male 2,247 (69.5%) 2,044 (63.2%) 1,787 (55.3%) 
White 3,031 (94.1%) 3,044 (94.4%) 3,067 (95.1%) 
Current smoker 262 (8.1%) 281 (8.7%) 372 (11.5%) 
Ex-smoker 1,590 (49.2%) 1,649 (51.0%) 1,655 (51.2%) 
Prior history of CVD 580 (17.9%) 700 (21.7%) 822 (25.4%) 
Known diabetes duration (years) 6 (3-10) 5 (2-10) 5 (2-9) 
BMI (kg/m
2
) 28.5 (25.8-31.8) 30.0 (27.0-33.5) 31.1 (27.9-35.4) 
Waist-to-hip ratio 0.93 (0.88-0.98) 0.94 (0.89-0.98) 0.94 (0.88-0.99) 
Fasting insulin (pmol/l) 60 (37-90) 72 (48-108) 90 (60-132) 
Fasting glucose (mmol/l) 8.3 (6.9-10.1) 8.4 (7.0-10.2) 8.7 (7.2-10.6) 
HbA1c (%) 6.8 (6.1-7.8) 6.8 (6.1-7.7) 7.0 (6.2-7.9) 
HbA1c (mmol/mol) 50.8 (42.6-61.2) 50.8 (42.6-60.7) 52.5 (43.7-62.8) 
HOMA-IR 1.44 (0.97-2.17) 1.76 (1.17-2.58) 2.16 (1.47-3.13) 
Systolic BP (mmHg) 139±15 141±15 142±15 
Diastolic BP (mmHg) 82±9 82±8 82±8 
Total cholesterol (mmol/l) 5.00±0.68 5.06±0.70 5.05±0.72 
HDL cholesterol (mmol/l) 1.13±0.27 1.09±0.25 1.07±0.25 
LDL cholesterol (mmol/l) 3.12±0.62 3.09±0.65 2.99±0.68 
Triacylglycerol (mmol/l) 1.50 (1.20-1.95) 1.76 (1.38-2.30) 1.99 (1.55-2.69) 
Apolipoprotein A-I (g/l) 1.30±0.21 1.29±0.21 1.29±0.21 
Apolipoprotein A-II (g/l) 0.35±0.07 0.35±.07 0.35±0.07 
Apolipoprotein B (g/l) 0.95±0.16 0.98±0.17 0.99±0.18 
Fibrinogen (g/l) 3.58±0.71 3.60±0.76 3.60±0.77 
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Plasma creatinine (μmol/l) 77.1±14.6 77.3±15.7 78.4±16.9 
Homocysteine (μmol/l) 9.2 (7.8-11.1) 9.5 (8.0-11.3) 10.0 (8.2-12.2) 
Estimated GFR (ml min
-1
 1.73 m
-2
) 89.7±17.5 88.2±18.4 85.2±19.0 
Data are expressed as mean ± SD, n (%) or median (IQR). 
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Table 2  Association of plasma FGF21 levels at baseline with outcome events over 5 years 
Outcomes HR (95% CI) 
 Model 1
a
 Model 2
b
 
Primary outcome:   
Total CVD events    
All subjects   
Tertile 2 1.35 (1.17, 1.55) 1.28 (1.10, 1.48) 
Tertile 3 1.45 (1.27, 1.67) 1.28 (1.10, 1.50) 
Overall effect p <0.001 0.002 
p for treatment interaction 0.07 0.04 
Placebo   
Tertile 2 1.55 (1.27, 1.88) 1.52 (1.24, 1.88) 
Tertile 3 1.49 (1.23, 1.81) 1.35 (1.08, 1.69) 
Overall effect p <0.001 <0.001 
Fenofibrate   
Tertile 2 1.15 (0.94, 1.41) 1.04 (0.84, 1.30) 
Tertile 3 1.42 (1.17, 1.72) 1.21 (0.97, 1.51) 
Overall effect p 0.002 0.19 
   
Secondary outcomes:   
CHD event   
Tertile 2 1.29 (1.04, 1.61) 1.16 (0.92, 1.47) 
Tertile 3 1.60 (1.29, 1.98) 1.23 (0.97, 1.57) 
Overall effect p <0.001 0.23 
p for treatment interaction 0.66 0.48 
   
Total stroke   
Tertile 2 1.47 (1.10, 1.95) 1.39 (1.02, 1.89) 
Tertile 3 1.75 (1.32, 2.30) 1.48 (1.08, 2.03) 
Overall effect p <0.001 0.04 
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p for treatment interaction 0.47 0.30 
   
CVD mortality    
Tertile 2 1.32 (0.96, 1.82) 1.11 (0.79, 1.57) 
Tertile 3 1.72 (1.27, 2.33) 1.14 (0.80, 1.62) 
Overall effect p 0.002 0.75 
p for treatment interaction 0.51 0.35 
   
Coronary & carotid revascularisation   
Tertile 2 1.43 (1.18, 1.72) 1.37 (1.12, 1.67) 
Tertile 3 1.32 (1.09, 1.60) 1.26 (1.01, 1.56) 
Overall effect p <0.001 0.007 
p for treatment interaction 0.14 0.28 
   
Tertiary outcomes:   
Hospitalisation for angina pectoris   
Tertile 2 1.62 (1.27, 2.07) 1.42 (1.10, 1.84) 
Tertile 3 1.82 (1.43, 2.32) 1.51 (1.15, 1.98) 
Overall effect p <0.001 0.007 
p for treatment interaction 0.77 0.48 
For all the outcomes, tertile 1 was the referent group for comparison. 
a
Adjusted for treatment allocation. 
b
Further adjusted for age, sex, known diabetes duration, prior history of CVD, smoking 
(never, former and current), BMI, HbA1c, HOMA-IR, systolic BP, HDL cholesterol, LDL 
cholesterol, triacylglycerol, fibrinogen, plasma creatinine and homocysteine at baseline. 
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Table 3  Assessing the incremental value of loge-transformed FGF21 levels using integrated discrimination improvement and net reclassification 
improvement  
Outcome IDI 95% CI NRI (>0) 95% CI Event NRI
a
 Nonevent NRI
b
 
Total CVD events       
All subjects 0.001
c
 0.000, 0.003 10.9%
c
 2.8%, 17.0% 5.4% 5.5% 
Placebo 0.005
c
 0.000, 0.005 13.8%
c
 2.4%, 23.1% 9.4% 4.3% 
Fenofibrate 0.000 0.000, 0.003 6.3% -6.2%, 17.3% 0.8% 5.5% 
CHD event 0.000 0.000, 0.002 8.4% -8.5%, 17.9% 4.8% 3.7% 
Total stroke 0.001
c
 0.000, 0.004 17.1%
c
 3.4%, 29.0% 10.7% 6.4% 
CVD mortality 0.001 0.000, 0.008 4.4% -8.7%, 22.7% -1.6% 6.0% 
Coronary & carotid revascularisation 0.000 0.000, 0.002 8.5% -4.5%, 15.9% 4.1% 4.4% 
Hospitalisation for angina pectoris 0.000 0.000, 0.003 12.4%
c
 1.4%, 20.9% 6.4% 6.0% 
Comparison are to be made for the addition of FGF21 (loge-transformed) to a model containing treatment allocation, age, sex, known diabetes 
duration, prior history of CVD, smoking (never, former and current), BMI, HbA1c, HOMA-IR, systolic BP, HDL cholesterol, LDL cholesterol, 
triacylglycerol, fibrinogen, plasma creatinine and homocysteine at baseline.  
The category-less NRI(>0) was calculated to quantify the improvement gained due to correct upward or downward change in predicted risks and 
is calculated as the proportion of event patients with correct upward or downward change minus incorrect upward or downward change plus the 
corresponding proportion among non-event patients.  The IDI was calculated to measure the difference in discrimination slopes between models.  
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The discrimination slope is the mean predicted risk of event among event patients minus the mean predicted risk of event among non-event 
patients and thus provides a measure of separation in predicted probabilities for event and nonevent.  Values above zero for the NRI and IDI 
indicate improved risk prediction and discrimination with the addition of FGF21 to the model. 
a
Percentage correctly reclassified among subjects who had events. 
b
Percentage correctly reclassified among subjects who did not have events. 
c
p<0.05. 
 
 
 
 


